Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer

This is a prospective, phase II, stratified single arm investigation for favorable prognosis in p16+ oropharynx cancer patients with either node negative or malignant neck adenopathy with lymphoscintigraphy mapping confined to the ipsilateral neck.

Trial Details

NCT ID
NCT05800574
Phase
PHASE2
Sponsor
Fox Chase Cancer Center
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Radiation therapy (5 days for 7 weeks)
  • Radiation therapy (5 days for 6 weeks)
  • Cisplatin
Locations (sample)
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362

Key Eligibility Criteria

  • Pathologically confirmed squamous cell carcinoma of the oropharynx
  • Patients to be treated with bilateral neck radiation per current guidelines must have either present (see below):
  • Nodal status (based on staging manual, AJCC (American Joint Committee on Cancer) 8th ed.): N0 (provided the tumor is within 1cm of midline) N1\> 1 …
  • Tumor stage T1-2 that approaches within 1 cm but does not cross midline as appreciated radiographically and/or by the treating radiation oncologist…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →